Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Status:
Terminated
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase 4, open-label, single-dose, parallel-group, multicenter, safety study of
cefazolin (1 g or 2 g) in pediatric subjects between 10 and 17 years of age (inclusive)
scheduled for surgery.